https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-02-01 / Scand. J. Immunol. 2005 Feb;61(2):147-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-02-01 / Scand. J. Immunol. 2005 Feb;61(2):147-562005-02-01 00:00:002019-02-15 08:50:24Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Nutr Cancer 2005;53(2):177-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Nutr Cancer 2005;53(2):177-932005-01-01 00:00:002019-02-15 08:50:23Chemo-immunotherapy of breast cancer using vesiculated alpha-tocopheryl succinate in combination with dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Curr. Pharm. Des. 2005;11(27):3475-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Curr. Pharm. Des. 2005;11(27):3475-832005-01-01 00:00:002019-02-15 08:50:23Immunotherapy and cancer vaccines in the management of breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-01 / Cancer Res. 2004 Nov;64(21):8022-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-01 / Cancer Res. 2004 Nov;64(21):8022-82004-11-01 00:00:002019-02-15 08:50:25Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-07-15 / Clin. Cancer Res. 2004 Jul;10(14):4699-708
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-07-15 / Clin. Cancer Res. 2004 Jul;10(14):4699-7082004-07-15 00:00:002004-07-15 00:00:00Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-06-08 / Cancer Immunol. Immunother. 2004 Sep;53(9):777-85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-06-08 / Cancer Immunol. Immunother. 2004 Sep;53(9):777-852004-06-08 00:00:002019-02-15 08:50:26Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-02-25 / Cancer Immunol Immunother 2004 Jul;53(7):633-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-02-25 / Cancer Immunol Immunother 2004 Jul;53(7):633-412004-02-25 00:00:002023-03-07 13:15:18Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-01-01 / Breast Dis 2004;20:65-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-01-01 / Breast Dis 2004;20:65-712004-01-01 00:00:002004-01-01 00:00:00Dendritic cell-based therapeutics for breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-01-01 / Cytotherapy 2004;6(2):154-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-01-01 / Cytotherapy 2004;6(2):154-632004-01-01 00:00:002019-02-15 08:50:27The immune response to breast cancer, and the case for DC immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-01 / Clin. Cancer Res. 2003 Oct;9(12):4376-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-01 / Clin. Cancer Res. 2003 Oct;9(12):4376-862003-10-01 00:00:002019-02-15 08:50:28Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells
